11/6
07:30 am
rntx
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
Low
Report
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
11/3
06:10 pm
rntx
Rein Therapeutics (NASDAQ:RNTX) was given a new $6.00 price target on by analysts at Loop Capital.
High
Report
Rein Therapeutics (NASDAQ:RNTX) was given a new $6.00 price target on by analysts at Loop Capital.
11/3
05:03 pm
rntx
Rein Therapeutics (NASDAQ:RNTX) was upgraded by analysts at Brookline Capital Management to a "buy" rating.
High
Report
Rein Therapeutics (NASDAQ:RNTX) was upgraded by analysts at Brookline Capital Management to a "buy" rating.
11/3
07:30 am
rntx
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Medium
Report
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
10/9
08:01 am
rntx
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
Low
Report
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
10/9
07:30 am
rntx
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Medium
Report
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
9/23
06:11 am
rntx
Rein Therapeutics (NASDAQ:RNTX) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Medium
Report
Rein Therapeutics (NASDAQ:RNTX) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
9/22
06:33 am
rntx
Rein Therapeutics (NASDAQ:RNTX) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Low
Report
Rein Therapeutics (NASDAQ:RNTX) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
9/17
07:30 am
rntx
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
Low
Report
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis